The US Food and Drug Administration continues to defy the constraints of the pandemic by not only meeting but exceeding user fee goal dates for a steady, high volume of approval actions.
The speed of FDA review can be seen particularly for the novel agents, a closely-watched regulatory metric. Three of the four recent new molecular entity approvals came at least one...